International Journal of Antimicrobial Agents
Volume 39, Issue 2 , Pages 96-104, February 2012

New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance

  • Ian M. Gould

      Affiliations

    • Department of Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1224 554 954; fax: +44 1224 550 632.
  • ,
  • Michael Z. David

      Affiliations

    • Departments of Medicine, Health Studies, and Pediatrics, University of Chicago, Chicago, IL, USA
  • ,
  • Silvano Esposito

      Affiliations

    • Dipartimento di Medicina Pubblica Clinica e Preventiva, Sezione Malattie Infettive, Seconda Università degli Studi di Napoli, Napoli, Italy
  • ,
  • Javier Garau

      Affiliations

    • Department of Medicine, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain
  • ,
  • Gerard Lina

      Affiliations

    • Centre National de Référence des Staphylocoques, Université Lyon, INSERM, Hospices Civils de Lyon, Lyon, France
  • ,
  • Teresita Mazzei

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, Florence, Italy
  • ,
  • Georg Peters

      Affiliations

    • Institute of Medical Microbiology, Münster, Germany

published online 26 December 2011.

Abstract 

Meticillin-resistant Staphylococcus aureus (MRSA) remains one of the principal multiply resistant bacterial pathogens causing serious healthcare-associated and community-onset infections. This paper reviews recent studies that have elucidated the virulence strategies employed by MRSA, key clinical trials of agents used to treat serious MRSA infections, and accumulating data regarding the implications of antibacterial resistance in MRSA for clinical success during therapy. Recent pre-clinical data support a species-specific role for Panton–Valentine leukocidin in the development of acute severe S. aureus infections and have elucidated other virulence mechanisms, including novel modes of internalisation, varying post-invasion strategies (featuring both upregulation and downregulation of virulence factors) and phenotypic switching. Recent double-blind, randomised, phase III/IV clinical trials have demonstrated the efficacy of linezolid and telavancin in hospital-acquired pneumonia (HAP) and complicated skin and skin-structure infections (cSSSIs) caused by MRSA. Tigecycline was non-inferior to imipenem/cilastatin in non-ventilator-associated HAP but was inferior in ventilator-associated pneumonia and has shown a higher rate of death than comparators on meta-analysis. Ceftaroline was clinically and microbiologically non-inferior to vancomycin/aztreonam in the treatment of MRSA cSSSI. Key resistance issues include a rise in vancomycin minimum inhibitory concentrations in MRSA, reports of clonal isolates with linezolid resistance mediated by acquisition of the chloramphenicol/florfenicol resistance gene, and case reports of daptomycin resistance resulting in clinical failure. Novel antimicrobial targets must be identified with some regularity or we will face the risk of untreatable S. aureus infections.

Keywords: Drug resistance, Meticillin-resistant Staphylococcus aureus, Pneumonia, Staphylococcal skin infections, Virulence

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This review is based on discussions held at the International Society of Chemotherapy (ISC) MRSA Consensus Meeting, 15–16 March 2011, Florence, Italy.

PII: S0924-8579(11)00459-6

doi:10.1016/j.ijantimicag.2011.09.028

International Journal of Antimicrobial Agents
Volume 39, Issue 2 , Pages 96-104, February 2012